News coverage about Acorda Therapeutics (NASDAQ:ACOR) has trended somewhat positive recently, Accern reports. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Acorda Therapeutics earned a coverage optimism score of 0.19 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 45.3522778656664 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Acorda Therapeutics (NASDAQ ACOR) traded down 0.64% on Friday, hitting $23.45. 316,739 shares of the stock were exchanged. The firm’s market cap is $1.09 billion. The company has a 50-day moving average of $22.15 and a 200 day moving average of $20.07. Acorda Therapeutics has a 12 month low of $13.60 and a 12 month high of $33.00.

Acorda Therapeutics (NASDAQ:ACOR) last announced its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $0.29 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.13 by $0.16. The firm had revenue of $139.40 million for the quarter, compared to the consensus estimate of $139.81 million. Acorda Therapeutics had a negative net margin of 8.02% and a negative return on equity of 6.37%. The company’s revenue was up 9.3% on a year-over-year basis. During the same period last year, the firm earned $0.07 EPS. Equities research analysts expect that Acorda Therapeutics will post $1.71 earnings per share for the current fiscal year.

A number of equities research analysts recently commented on ACOR shares. Cowen and Company reaffirmed an “outperform” rating and issued a $35.00 price target on shares of Acorda Therapeutics in a report on Wednesday, June 7th. BidaskClub raised shares of Acorda Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Friday, July 7th. Stifel Nicolaus reaffirmed a “buy” rating on shares of Acorda Therapeutics in a report on Friday, July 28th. J P Morgan Chase & Co set a $24.00 price target on shares of Acorda Therapeutics and gave the stock a “hold” rating in a report on Tuesday, June 6th. Finally, Janney Montgomery Scott reaffirmed a “hold” rating and issued a $18.00 price target on shares of Acorda Therapeutics in a report on Wednesday, August 30th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, two have given a buy rating and one has issued a strong buy rating to the stock. Acorda Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $24.36.

TRADEMARK VIOLATION WARNING: “Acorda Therapeutics (ACOR) Earning Somewhat Positive Press Coverage, Study Finds” was originally posted by Watch List News and is the property of of Watch List News. If you are reading this story on another domain, it was illegally copied and republished in violation of international copyright and trademark laws. The legal version of this story can be viewed at

In other news, major shareholder Scopia Capital Management Lp acquired 766,201 shares of the firm’s stock in a transaction dated Tuesday, August 29th. The shares were purchased at an average cost of $19.23 per share, for a total transaction of $14,734,045.23. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Barry E. Greene sold 10,000 shares of the firm’s stock in a transaction on Tuesday, August 1st. The shares were sold at an average price of $21.57, for a total transaction of $215,700.00. Following the sale, the director now owns 10,000 shares in the company, valued at $215,700. The disclosure for this sale can be found here. 7.90% of the stock is owned by company insiders.

Acorda Therapeutics Company Profile

Acorda Therapeutics, Inc is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS).

Insider Buying and Selling by Quarter for Acorda Therapeutics (NASDAQ:ACOR)

Receive News & Ratings for Acorda Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.